SeaStar Medical reports Q1 2026 revenue of $495K, a 69% increase, while narrowing net loss to $3.5M. Discover their strategic initiatives and future outlook.

Key Takeaways

• Net revenue from Quelimmune sales reached $495,000 in Q1 2026, a 69% increase from $293,000 in Q1 2025.
• Gross profit margin maintained over 90%, consistent with prior quarters.
• Net loss narrowed to $3.5 million ($0.90 per share) from $3.8 million ($4.38 per share) year-over-year.
• Cash balance improved to $9.3 million as of March 31, 2026, up from $5.2 million a year earlier.
• Enrollment in the Neutralize AKI pivotal trial reached 198 patients, with a goal of 339 by year-end 2026.

Financial Performance

In the first quarter of 2026, SeaStar Medical Holding Corporation reported a net revenue of approximately $495,000 from Quelimmune sales, marking a remarkable 69% increase from $293,000 in the same period last year. This growth reflects the company’s commitment to expanding its presence in pediatric hospitals and enhancing the adoption of its innovative therapies for acute kidney injury (AKI).

The gross profit margin remained robust at over 90%, consistent with the previous three quarters. This high margin is attributed to the company’s effective cost management strategies and the successful transition from research and development to commercialization of its products.

Despite the positive revenue growth, the company reported a net loss of approximately $3.5 million, which represents a slight improvement from the $3.8 million loss in Q1 2025. This translates to a loss of $0.90 per share, based on approximately 3.9 million shares outstanding. The improved cash balance of $9.3 million as of March 31, 2026, compared to $5.2 million one year prior, indicates a stronger financial position and supports ongoing operational initiatives.

Strategic Initiatives

SeaStar Medical continues to focus on growing its market presence through strategic initiatives aimed at expanding the use of Quelimmune therapy in pediatric settings. The company is actively onboarding new clinical sites for its Neutralize AKI pivotal trial, which aims to assess the efficacy of its SCD therapy in critically ill adult patients. As of now, 198 out of the targeted 339 patients have been enrolled, with expectations to complete enrollment by the end of 2026.

Management has highlighted the importance of education and collaboration with healthcare providers. Monthly virtual clinical user calls with pediatric nephrology and critical care teams are fostering a community where experiences and outcomes are shared, thereby enhancing the understanding and adoption of Quelimmune therapy.

Additionally, the company announced the completion of enrollment in its SAVE Registry, which tracks the commercial use of Quelimmune in critically ill children. This registry is crucial for gathering safety data and facilitating a transition from mandatory to voluntary post-marketing studies, which would reduce administrative burdens on children's hospitals and accelerate therapy adoption.

Future Outlook

Looking ahead, SeaStar Medical remains optimistic about its growth trajectory. The management team is focusing on accelerating the enrollment process in clinical trials while maintaining a disciplined approach to operating expenses. Research and development expenditures are expected to increase modestly by approximately 5% each quarter as the company supports additional clinical sites.

Management’s guidance includes plans to submit a modular Premarket Approval (PMA) application to the FDA, which would enable earlier reviews of non-clinical trial data. This strategy aims to streamline the approval process for the SCD therapy, potentially leading to commercialization without the regulatory barriers faced by Quelimmune.

Furthermore, the recognition of SCD therapy in prominent nephrology publications, such as the American Society of Nephrology's Kidney News, is a significant milestone that underscores the therapy's growing acceptance in the medical community. The company is actively working on establishing relationships with key nephrologists, which will be vital as it prepares for potential launches of its SCD therapy for adult indications in the future.

Conclusion

In summary, SeaStar Medical Holding Corporation has made substantial strides in its financial performance and strategic initiatives during the first quarter of 2026. The significant revenue growth, robust gross margins, and improved cash position highlight the company's potential for future success. As it continues to expand its market presence and navigate the regulatory landscape, SeaStar Medical is well-positioned to capitalize on its innovative therapies for acute kidney injury and reshape treatment paradigms in pediatric care.

This analysis is based on public earnings call materials and is not investment advice.